» Articles » PMID: 37446046

Diverse Sphingolipid Profiles in Rectal and Colon Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jul 14
PMID 37446046
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is a heterogenous group of neoplasms showing a variety of clinical and pathological features depending on their anatomical location. Sphingolipids are involved in the formation and progression of cancers, and their changes are an important part of the abnormalities observed during carcinogenesis. Because the course of rectal and colonic cancer differs, the aim of the study was to assess whether the sphingolipid profile is also different in tumors of these two regions. Using a combination of ultra-high-performance liquid chromatography combined with triple quadrupole mass spectrometry, differences in the amounts of cellular sphingolipids were found in colorectal cancer. Sphingosine content was higher in rectal cancer than in adjacent healthy tissue, while the content of two ceramides (C18:0-Cer and C20:0-Cer) was lower. In colon cancer, a higher content of sphingosine, sphinganine, sphingosine-1-phosphate, and two ceramides (C14:0-Cer and C24:0-Cer) was found compared to healthy tissue, but there was no decrease in the amount of any of the assessed sphingolipids. In rectal cancer, the content of sphinganine and three ceramides (C16:0-Cer, C22:0-Cer, C24:0-Cer), as well as the entire pool of ceramides, was significantly lower compared to colon cancer. The S1P/Cer ratio in rectal cancer (S1P/C18:1-Cer, S1P/C20:0-Cer, S1P/C22:0-Cer, S1P/C24:1-Cer) and in colon cancer (S1P/C18:0-Cer, S1P/C18:1-Cer, S1P/C20:0-Cer) was higher than in adjacent healthy tissue and did not differ between the two sites (rectal cancer vs. colonic cancer). It seems that the development of colorectal cancer is accompanied by complex changes in the metabolism of sphingolipids, causing not only qualitative shifts in the ceramide pool of cancer tissue but also quantitative disturbances, depending on the location of the primary tumor.

Citing Articles

Metabolomics insights into doxorubicin and 5-fluorouracil combination therapy in triple-negative breast cancer: a xenograft mouse model study.

Hassanein M, Hagyousif Y, Zenati R, Al-Hroub H, Khan F, Abuhelwa A Front Mol Biosci. 2025; 11:1517289.

PMID: 39872164 PMC: 11769812. DOI: 10.3389/fmolb.2024.1517289.


Role of dietary and nutritional interventions in ceramide-associated diseases.

Wang S, Jin Z, Wu B, Morris A, Deng P J Lipid Res. 2024; 66(1):100726.

PMID: 39667580 PMC: 11754522. DOI: 10.1016/j.jlr.2024.100726.


The role of ACER2 in intestinal sphingolipid metabolism and gastrointestinal cancers.

Liu B, Zhou J, Jiang B, Tang B, Liu T, Lei P Front Immunol. 2024; 15:1511283.

PMID: 39650647 PMC: 11621088. DOI: 10.3389/fimmu.2024.1511283.


How ceramides affect the development of colon cancer: from normal colon to carcinoma.

Merz N, Hartel J, Grosch S Pflugers Arch. 2024; 476(12):1803-1816.

PMID: 38635059 PMC: 11582153. DOI: 10.1007/s00424-024-02960-x.


Oral Administration of Glucosylceramide Suppresses Tumor Growth by Affecting the Ceramide/Sphingosine-1-Phosphate Balance in Breast Cancer Tissue.

Moro K, Ichikawa H, Koyama Y, Abe S, Uchida H, Naruse K World J Oncol. 2023; 14(5):430-437.

PMID: 37869237 PMC: 10588502. DOI: 10.14740/wjon1656.

References
1.
Campbell W, Spence R, Parks T . Familial adenomatous polyposis. Br J Surg. 1994; 81(12):1722-33. DOI: 10.1002/bjs.1800811207. View

2.
Liu X, Cheng J, Turner L, Elojeimy S, Beckham T, Bielawska A . Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009; 13(12):1449-58. PMC: 2796572. DOI: 10.1517/14728220903357512. View

3.
Moro K, Kawaguchi T, Tsuchida J, Gabriel E, Qi Q, Yan L . Ceramide species are elevated in human breast cancer and are associated with less aggressiveness. Oncotarget. 2018; 9(28):19874-19890. PMC: 5929433. DOI: 10.18632/oncotarget.24903. View

4.
Blachnio-Zabielska A, Persson X, Koutsari C, Zabielski P, Jensen M . A liquid chromatography/tandem mass spectrometry method for measuring the in vivo incorporation of plasma free fatty acids into intramyocellular ceramides in humans. Rapid Commun Mass Spectrom. 2012; 26(9):1134-40. PMC: 3370409. DOI: 10.1002/rcm.6216. View

5.
Ahn E, Schroeder J . Induction of apoptosis by sphingosine, sphinganine, and C(2)-ceramide in human colon cancer cells, but not by C(2)-dihydroceramide. Anticancer Res. 2010; 30(7):2881-4. View